3rd Annual Gene Therapy for Rare Disorders Europe, London (UK)

GenSight Biologics to present new GS010 data at the 2019 Annual Meeting of the American Academy of Ophthalmology

Future is now: Leaders in Ocular Gene Therapy Meeting, San Francisco (CA)

EURETINA 2019 Congress, Paris, France

UMDF Mitochondrial Medicine 2019, Washington DC, US

GenSight Biologics announces presentation of results from the REVERSE Phase III trial of GS010 at the 14th meeting of the European Neuro-Ophthalmology Society (EUNOS)

14th Meeting of EUNOS, Porto, Portugal

2019 SOE Congress, European Society of Ophthalmology, Nice, France

BIO International Convention, Philadelphia, PA (US)

Sustained bilateral improvement from GenSight Biologics’ REVERSE Phase III clinical trial represents transformative therapeutic benefit for patients, Key Opinion Leaders conclude